Supplymentary Table 1 Patients' characteristics according to tumor location: left colon/right colon/rectum

	Left colon + sigmoid	Right colon + transverse colon	Rectum	pValue
Age				0,0507
N	203	174	89	
Mean (std)	63.1 (11.6)	65.7 (10.9)	62.7 (12.6)	
Median [min - max]	64.0 [24.0 - 91.0]	66.0 [29.0 - 92.0]	62.0 [30.0 - 89.0]	
Gender				0,3860
Male	111 (54.7%)	90 (51.7%)	54 (60.7%)	
Female	92 (45.3%)	84 (48.3%)	35 (39.3%)	
PS				0,0075
0-1	128 (88.3%)	103 (75.7%)	69 (88.5%)	
2-4	17 (11.7%)	33 (24.3%)	9 (11.5%)	
Missing values	58	38	11	
Number of metastatic sites				0,0333
1	135 (66.5%)	92 (52.9%)	56 (62.9%)	
2	48 (23.6%)	57 (32.8%)	28 (31.5%)	
> 2	20 (9.9%)	25 (14.4%)	5 (5.6%)	
Metastatic sites :				
Liver				0,2211
No	35 (17.2%)	40 (23.3%)	14 (15.7%)	
Yes	168 (82.8%)	132 (76.7%)	75 (84.3%)	
Missing values	0	2	0	

Lung				0,0050
No	159 (78.7%)	129 (75.0%)	54 (60.7%)	
Yes	43 (21.3%)	43 (25.0%)	35 (39.3%)	
Missing values	1	2	0	
Peritoneum				< 0.0001
No	159 (78.7%)	112 (65.1%)	85 (95.5%)	
Yes	43 (21.3%)	60 (34.9%)	4 (4.5%)	
Missing values	1	2	0	
Other				0,3677
No	160 (79.2%)	128 (74.9%)	73 (82.0%)	
Yes	42 (20.8%)	43 (25.1%)	16 (18.0%)	
Missing values	1	3	0	
KRAS mutation				0,0066
No	104 (65.8%)	58 (47.5%)	40 (52.6%)	
Yes	54 (34.2%)	64 (52.5%)	36 (47.4%)	
Missing values	45	52	13	
BRAF mutation				0,0007
No	124 (94.7%)	80 (80.8%)	61 (95.3%)	
Yes	7 (5.3%)	19 (19.2%)	3 (4.7%)	
Missing values	72	75	25	
CEA				0,9520
< = 200	107 (69.0%)	94 (67.6%)	50 (69.4%)	
> 200	48 (31.0%)	45 (32.4%)	22 (30.6%)	
Missing values	48	35	17	

LDH				0,7965
< = 254	73 (52.1%)	65 (52.4%)	37 (56.9%)	
> 254	67 (47.9%)	59 (47.6%)	28 (43.1%)	
Missing values	63	50	24	
Leukocytes > 10000				0,5688
No	109 (73.2%)	100 (70.9%)	47 (66.2%)	
Yes	40 (26.8%)	41 (29.1%)	24 (33.8%)	
Missing values	54	33	18	
Alkaline phosphatase > 300				0,0130
No	118 (84.9%)	91 (70.0%)	52 (78.8%)	
Yes	21 (15.1%)	39 (30.0%)	14 (21.2%)	
Missing values	64	44	23	
PTR				0,0010
No	50 (24.6%)	62 (35.6%)	41 (46.1%)	
Yes	153 (75.4%)	112 (64.4%)	48 (53.9%)	
Oxaliplatin				0,7809
No	14 (6.9%)	15 (8.6%)	6 (6.7%)	
Yes	189 (93.1%)	159 (91.4%)	83 (93.3%)	
5 FU or capecitabine				0,5995
No	1 (0.5%)	2 (1.1%)	0 (0.0%)	
Yes	202 (99.5%)	172 (98.9%)	89 (100.0%)	
Irinotecan				0,2047
No	47 (23.3%)	44 (25.3%)	14 (15.7%)	
Yes	155 (76.7%)	130 (74.7%)	75 (84.3%)	
Missing values	1	0	0	

Bevacizumab				0,5383
No	71 (35.1%)	52 (30.2%)	27 (30.3%)	
Yes	131 (64.9%)	120 (69.8%)	62 (69.7%)	
Missing values	1	2	0	
EGFR inhibitors				0,0013
No	99 (49.0%)	117 (67.6%)	51 (57.3%)	
Yes	103 (51.0%)	56 (32.4%)	38 (42.7%)	
Missing values	1	1	0	
1st line chemotherapy regimen				0,0045
Mono-chemotherapy	16 (8.0%)	23 (13.4%)	9 (10.1%)	
Bi-chemotherapy	148 (73.6%)	126 (73.3%)	52 (58.4%)	
Tri-chemotherapy	37 (18.4%)	23 (13.4%)	28 (31.5%)	
Missing values	2	2	0	
Lung or liver surgery or radio-frequency				0,0267
No	136 (67.7%)	134 (77.5%)	56 (62.9%)	
Yes	65 (32.3%)	39 (22.5%)	33 (37.1%)	
Missing values	2	1	0	

PS: Performans status; CEA: Carcinoembryonic antigen; LDH: Lactate dehydrogenase; PTR: Primary tumor resection; 5FU: 5 Fluorouracil; EGFR: Epidermal growth factor.